Saltar al contenido
Merck

[A case in which tofisopam was effective for treatment of paroxysmal supraventricular tachycardia].

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan (2003-05-30)
Ryuji Kato, Kazuya Ooi, Kazuyuki Ueno
RESUMEN

Paroxysmal supraventricular tachycardia (PSVT) is a reentrant tachycardia, and the autonomic nervous system influences the paroxysms of PSVT. Tofisopam (Grandaxin) is a derivative of benzodiazepines. It is reported that heart rate variability (HRV) reveals the function of the autonomic nervous system and is used as an index of the effects of the autonomic nervous system on the heart rhythm. In previous studies, it was reported that tofisopam improved HRV. In this case report, the frequency of PSVT was significantly decreased and subjective symptoms of arrhythmia were eliminated after the administration of tofisopam. R-R interval variability and high-frequency power (HF; 0.15-0.40 Hz) were increased, and [low-frequency power (LF; 0.04-0.15 Hz)]/HF was decreased after administration of tofisopam. These results suggest that tofisopam overcame the existing imbalance of the sympathetic and vagus nervous system. In this case report, it is suggested that tofisopam is effective for the treatment of PSVT.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Tofisopam, ≥98% (HPLC), solid